Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, Marianne E, Prof ; Hainsworth, John D, Prof ; Baudin, Eric, MD ; Peeters, Marc, Prof ; Hörsch, Dieter, Prof ; Winkler, Robert E, MD ; Klimovsky, Judith, MD ; Lebwohl, David, MD ; Jehl, Valentine, MSc ; Wolin, Edward M, MD ; Öberg, Kjell, Prof ; Van Cutsem, Eric, Prof ; Yao, James C, Dr

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível